We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GNPX:NASDAQGenprex, Inc. Analysis

Data as of 2026-10-02 - not real-time

$2.68

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Genprex, Inc. trades at $2.68, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. The last 30 days have lost 32.2%. Relative strength is 29.8 — oversold — and the MACD signal is bullish. The recent range runs from support at $2.53 up to resistance at $4.20.
Multiples put this in undervalued territory: 0.1 times earnings against the sector's 29.7.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 78.3%, a beta of 1.68 and a maximum drawdown of 99.7%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.

Top Market Events

Genprex Inc. NASDAQ:GNPX shares gained 3% on Monday after the clinical-stage biotechnology company announced a...Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future.../PRNewswire/ -- Genprex, Inc. "Genprex" or the "Company" NASDAQ: GNPX , a clinical-stage gene therapy company focused...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • RSI at 29.8 signals oversold conditions
  • Trading below the 200-day average of 24.75

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • RSI at 29.8 signals oversold conditions
  • P/E of 0.1 versus sector average of 29.7

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • P/E of 0.1 versus sector average of 29.7
  • Negative return on equity of -203.9%
  • Negative free cash flow

Key Metrics & Analysis

Financial Health

P/E Ratio0.1
ROE-203.86%
ROA-94.46%
P/B Ratio0.1
Op. Cash Flow$-15562704
Free Cash Flow$-10575076
Industry P/E29.7

Technical Analysis

TrendBearish
RSI29.8
Support$2.53
Resistance$4.20
MA 20$3.28
MA 50$4.14
MA 200$24.75
MACDBullish
VolumeIncreasing
Fear & Greed Index93.41

Valuation

GradeUndervalued
TypeBlend

Risk Assessment

Beta1.68
Volatility78.35%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.